Physician profile
Diane C Scheuer
NPI 1407841943
$1,528.63
in general payments reported to CMS, 2019-2025
24 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $643 · 2021: $17.06 · 2024: $13.52 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $168.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $257.60 | 2019-2020 | |
| Pfizer INC. | $158.47 | 2019-2020 | |
| Glaxosmithkline, LLC. | $154.51 | 2019-2025 | Nucala, Arexvy, Shingrix |
| Amarin Pharma, INC. | $132.48 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.05 | 2019-2025 | |
| Novo Nordisk INC | $128.03 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $75.09 | 2019-2020 | |
| Lilly USA, LLC | $64.36 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.51 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $46.05 | 2020-2025 | Zoryve |
| Gilead Sciences, INC. | $45.97 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $42.96 | 2019 | |
| Shire North American Group INC | $36.09 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.89 | 2019-2020 | |
| Exact Sciences Corporation | $28.97 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $23.35 | 2025 | Symbravo |
| Amgen INC. | $21.75 | 2019 | |
| Circassia INC. | $17.76 | 2019 | |
| Genentech USA, INC. | $16.14 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.94 | 2020 | |
| Antares Pharma, INC. | $14.62 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.20 | 2019 | |
| Daiichi Sankyo INC. | $13.48 | 2020 | |
| Allergan, INC. | $13.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Scheuer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.